一种基于循环的放射性疗效剂,用于基因酶类型的质激素激活剂在瘤中
Xingkai Wang1, Dong Dai2,3, Jieting Shen1
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xian Nong Tan Street, Beijing, China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|March 18, 2025
概括
研究人员开发了一种新型的PET追踪剂,即[64Cu]CAP-1,用于可视化尿酶类型的质激素激活剂 (uPA) 在瘤中. 这种标记物显示出作为放射性耐辐射剂的前景,有效抑制瘤生长并改善小鼠模型中的存活率.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 放射化学 放射化学是指辐射化学.
背景情况:
- 血原激活器系统,特别是尿素酶类型的血原激活器 (uPA),在瘤进展,入侵和转移中发挥着至关重要的作用.
- 异常的uPA激活促进了细胞外基质的降解,使uPA成为癌症诊断和治疗的重要目标.
研究的目的:
- 设计和评估新型循环基放射连体作为正电子发射断层扫描 (PET) 标记器,用于在临床前癌症模型中可视化uPA.
- 为了确定一个最佳的辐射追踪器,以准确检测uPA和潜在的治疗应用.
主要方法:
- 三个带有铜-64.4标记的循环放射性连体 ([64Cu]CAP-1,[64Cu]CAP-2,[64Cu]CAP-3) 的合成和表征.
- 在小鼠瘤模型中评估放射性链体的结合亲和力,特异性和药物动力学概况.
- 将最佳候选物 ([64Cu]CAP-1) 与临床上先进的标记物 ([64Cu]DOTA-AE105) 的比较.
- 评估[64Cu]CAP-1在抑制瘤生长和延长存活时间方面的疗效.
主要成果:
- [64Cu]CAP-1,具有原生二硫化物键,被确定为主要候选物.
- 与[64Cu]DOTA-AE105.5相比,[64Cu]CAP-1表现出优越的瘤吸收和较低的肝脏积累.
- 在小鼠模型中,单剂量[64Cu]CAP-1显著抑制瘤生长并延长存活时间.
结论:
- [64Cu]CAP-1是一种高效的PET追踪器,用于uPA可视化.
- 这种放射性连接体显示出作为对UPA过度表达瘤的放射性异常剂的显著潜力.
- 这些发现突出了在癌症治疗中精确准uPA/uPAR轴的新策略.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...